COVID-19 and Emerging Viruses

Meeting Current Needs, Preparing for the Future

As a pioneer and leader in antiviral drug development, Gilead developed the first approved antiviral medicine for the treatment of COVID-19.

Building on more than three decades of research and virology leadership, we were able to quickly demonstrate our treatment's efficacy and safety and ramp up production to make it available to people who needed it the most.

This therapy has been made available to tens of millions of people around the world and is considered an antiviral standard of care for the treatment of COVID-19 — helping both hospitalized and non-hospitalized adult and pediatric patients. Today, Gilead is conducting real-world data analyses to understand how treatments available are being used in clinical practice and how the SARS-CoV-2 virus is evolving and impacting people, particularly those most susceptible to the virus.

As we know, SARS-CoV-2 isn't the only virus capable of a sparking a pandemic. To prepare, we’re applying our expertise in virology to combat other emerging viruses.

View Our Pipeline

Developing Urgently Needed Treatments

When a new pneumonia-like illness was identified as a novel coronavirus in December 2019, Gilead moved quickly to determine if our expertise in virology and experience studying coronaviruses could play a role. Now, building on our contributions during the pandemic, our research program includes a investigational therapy for respiratory syncytial virus (RSV).

Gilead-Scientist-Working-Protective-Gear

Preparing for the Next Pandemic

We're now studying a variety of viruses to discover and develop therapies. We’re in a unique position to make a difference with our decades-long experience in antivirals, our unwavering focus on innovation and our commitment to making lifesaving drugs available to people around the world.

Enabling Access

In a time of global crisis, access and equity are critically important. During the early days of the COVID-19 pandemic, we entered into voluntary licensing agreements with nine generic pharmaceutical manufacturers to make our antiviral available to millions of people in low- and middle-income countries. We formed a Patient Council to help us understand and address some of the unmet needs of people impacted by this virus and inform our education efforts.

We also collaborated with the Morehouse School of Medicine’s Satcher Health Leadership Institute and Google.org to develop the Health Equity Tracker, a first-of-its-kind, public-facing data platform that displays and contextualizes health disparities facing communities of color throughout the United States, with an initial focus on COVID-19.

Learn More About Medication Access

HIV

We’re pursuing advancements in HIV through scientific innovation and community partnerships.

Learn More

Viral Hepatitis

Gilead researchers are transforming the lives of people living with hepatitis B, C and D through groundbreaking science.

Learn More